Archived Comments for:
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
In figure 1, there is a mistake in the decision tree for patients treated with tolterodine and solifenacin. It is written that all patients are treated at the end of the study period with fesoterodine 4 mg but there is a mistake. Patients who started treatment with tolterodine or solifenacin discontinued or remained with the same treatment until the end of the study, they do not switched to fesoterodine.
mistake in figure 1
21 June 2011
In figure 1, there is a mistake in the decision tree for patients treated with tolterodine and solifenacin. It is written that all patients are treated at the end of the study period with fesoterodine 4 mg but there is a mistake. Patients who started treatment with tolterodine or solifenacin discontinued or remained with the same treatment until the end of the study, they do not switched to fesoterodine.
Competing interests
None declared